Related Experiment Videos
Intraocular sustained drug delivery using implantable polymeric devices.
Tsutomu Yasukawa1, Yuichiro Ogura, Eiji Sakurai
1Kurashiki Central Hospital, Kurashiki 710-8602, Japan; Department of Ophthalmology, Nagoya City University Medical School, Aichi 467-8601, Japan.
Advanced Drug Delivery Reviews
|November 3, 2005
Summary
Implantable drug delivery devices offer a promising solution for treating refractory vitreoretinal diseases like age-related macular degeneration (AMD). These systems aim to overcome the limitations of conventional drug administration for better therapeutic outcomes.
Area of Science:
- Ophthalmology
- Biomaterials Science
- Pharmacokinetics
Background:
- Vitreoretinal diseases, including age-related macular degeneration (AMD), present significant treatment challenges due to the unique pharmacokinetic barriers of the eye.
- Conventional drug delivery methods like eye drops and systemic administration achieve minimal therapeutic concentrations in the vitreoretinal tissue.
- The blood-retinal barriers limit effective drug penetration to the retina and vitreous cavity.
Purpose of the Study:
- To explore the potential of intraocular sustained drug release systems using implantable devices for treating various vitreoretinal diseases.
- To address the limitations of current drug delivery methods for chronic and severe ocular conditions.
- To investigate the feasibility of polymeric implants for targeted drug delivery in the eye.
Main Methods:
- Investigated the use of hydrophobic or hydrophilic polymers for creating implantable drug delivery devices.
- Explored various shapes for implants including sheets, discs, rods, and plugs.
- Considered multiple implantation sites: subretinal space, intrascleral space, vitreous space, peribulbar space, and pars plana.
- Evaluated the potential application for diseases such as cytomegalovirus retinitis, uveitis, proliferative vitreoretinopathy, AMD, macular edema, and retinitis pigmentosa.
Main Results:
- Intraocular sustained drug release via implantable devices is a viable strategy to overcome pharmacokinetic barriers.
- Polymeric implants can be designed in various forms and implanted in different ocular spaces.
- These systems show promise for chronic conditions like AMD and other diseases requiring sustained drug levels.
Conclusions:
- Implantable drug delivery systems represent a feasible and promising approach for managing vitreoretinal diseases.
- The development of such devices could significantly improve therapeutic outcomes for conditions refractory to conventional treatments.
- Further research into the feasibility of these implants, particularly for AMD, is strongly suggested by researchers.